CL2024001874A1 - Inhibidores de parp1. - Google Patents
Inhibidores de parp1.Info
- Publication number
- CL2024001874A1 CL2024001874A1 CL2024001874A CL2024001874A CL2024001874A1 CL 2024001874 A1 CL2024001874 A1 CL 2024001874A1 CL 2024001874 A CL2024001874 A CL 2024001874A CL 2024001874 A CL2024001874 A CL 2024001874A CL 2024001874 A1 CL2024001874 A1 CL 2024001874A1
- Authority
- CL
- Chile
- Prior art keywords
- parp1
- parp1 inhibitors
- treating
- inhibitors
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292903P | 2021-12-22 | 2021-12-22 | |
| US202263327228P | 2022-04-04 | 2022-04-04 | |
| US202263403459P | 2022-09-02 | 2022-09-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024001874A1 true CL2024001874A1 (es) | 2024-12-06 |
Family
ID=85156997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024001874A CL2024001874A1 (es) | 2021-12-22 | 2024-06-19 | Inhibidores de parp1. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250163022A1 (enExample) |
| EP (1) | EP4452963A1 (enExample) |
| JP (1) | JP2025501762A (enExample) |
| KR (1) | KR20240136978A (enExample) |
| AU (1) | AU2022420969A1 (enExample) |
| CA (1) | CA3241875A1 (enExample) |
| CL (1) | CL2024001874A1 (enExample) |
| CO (1) | CO2024009571A2 (enExample) |
| CR (1) | CR20240296A (enExample) |
| IL (1) | IL313727A (enExample) |
| MX (1) | MX2024007673A (enExample) |
| PE (1) | PE20242004A1 (enExample) |
| TW (1) | TW202332438A (enExample) |
| WO (1) | WO2023122140A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL305262A (en) | 2021-03-10 | 2023-10-01 | Jnana Therapeutics Inc | Small molecule inhibitors of mammalian SLC6A19 function |
| AU2023229992A1 (en) * | 2022-03-11 | 2024-10-10 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and the use thereof |
| US20250214980A1 (en) | 2022-03-14 | 2025-07-03 | Slap Pharmaceuticals Llc | Multicyclic compounds |
| AU2023299635A1 (en) * | 2022-06-27 | 2025-01-02 | Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd | Tricyclic compounds and uses thereof |
| CN115232129B (zh) * | 2022-08-18 | 2023-12-01 | 上海闻耐医药科技有限公司 | 一种parp1选择性抑制剂及其制备方法和用途 |
| CN120092010A (zh) * | 2022-11-02 | 2025-06-03 | 轩竹生物科技股份有限公司 | 多环类聚（adp核糖）聚合酶选择性抑制剂 |
| AU2023378452A1 (en) * | 2022-11-10 | 2025-06-19 | Haihe Biopharma Co., Ltd. | Fused tricyclic parp1 inhibitor, preparation method therefor, and use thereof |
| TW202506680A (zh) * | 2023-04-28 | 2025-02-16 | 美商思諾維新醫藥公司 | 作為ｐａｒｐ１抑制劑之雜環化合物 |
| CN119462669A (zh) * | 2023-08-11 | 2025-02-18 | 上海海和药物研究开发股份有限公司 | 稠合三环类化合物、其药物组合物和用途 |
| WO2025067417A1 (zh) * | 2023-09-28 | 2025-04-03 | 成都赜灵生物医药科技有限公司 | 并内酰胺环类化合物及其用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8541417B2 (en) * | 2009-07-30 | 2013-09-24 | Takeda Pharmaceutical Company Limited | Poly (ADP-ribose) polymerase (PARP) inhibitors |
| JPWO2015060348A1 (ja) * | 2013-10-23 | 2017-03-09 | 大日本住友製薬株式会社 | 縮合ピラゾール誘導体 |
| PT3312177T (pt) * | 2015-06-09 | 2021-05-17 | Onconic Therapeutics Inc | Composto derivado tricíclico, método para preparar o mesmo e composição farmacêutica compreendendo o mesmo |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2022
- 2022-12-21 WO PCT/US2022/053591 patent/WO2023122140A1/en not_active Ceased
- 2022-12-21 PE PE2024001409A patent/PE20242004A1/es unknown
- 2022-12-21 IL IL313727A patent/IL313727A/en unknown
- 2022-12-21 US US18/728,407 patent/US20250163022A1/en active Pending
- 2022-12-21 EP EP22851230.7A patent/EP4452963A1/en active Pending
- 2022-12-21 MX MX2024007673A patent/MX2024007673A/es unknown
- 2022-12-21 TW TW111149299A patent/TW202332438A/zh unknown
- 2022-12-21 KR KR1020247024155A patent/KR20240136978A/ko active Pending
- 2022-12-21 JP JP2024538278A patent/JP2025501762A/ja active Pending
- 2022-12-21 CA CA3241875A patent/CA3241875A1/en active Pending
- 2022-12-21 AU AU2022420969A patent/AU2022420969A1/en active Pending
- 2022-12-21 CR CR20240296A patent/CR20240296A/es unknown
-
2024
- 2024-06-19 CL CL2024001874A patent/CL2024001874A1/es unknown
- 2024-07-19 CO CONC2024/0009571A patent/CO2024009571A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022420969A1 (en) | 2024-06-13 |
| KR20240136978A (ko) | 2024-09-19 |
| US20250163022A1 (en) | 2025-05-22 |
| CO2024009571A2 (es) | 2024-07-29 |
| IL313727A (en) | 2024-08-01 |
| JP2025501762A (ja) | 2025-01-23 |
| CA3241875A1 (en) | 2023-06-29 |
| MX2024007673A (es) | 2024-09-06 |
| EP4452963A1 (en) | 2024-10-30 |
| WO2023122140A1 (en) | 2023-06-29 |
| PE20242004A1 (es) | 2024-10-03 |
| TW202332438A (zh) | 2023-08-16 |
| CR20240296A (es) | 2024-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2024009571A2 (es) | Inhibidores de parp1 | |
| ECSP22053394A (es) | Inhibidores de sarm1 | |
| CL2023000525A1 (es) | Inhibidores de sarm1 | |
| CO2023015484A2 (es) | Compuesto, composiciones y métodos para el tratamiento de trastornos | |
| JOP20180039A1 (ar) | مثبطات pd-1/pd-l1 | |
| CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| MX2021013815A (es) | Combinacion de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento contra el cancer. | |
| MX2018013848A (es) | Combinacion de anticuerpos anti-pd-1s y radiacion para tratar cancer. | |
| JOP20210050B1 (ar) | معدلات تعبير pnpla3 | |
| ECSP21053104A (es) | Moduladores de la expresión de hsd17b13 | |
| ECSP099723A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer | |
| DOP2009000243A (es) | Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer | |
| MX2022003689A (es) | Metodos y composiciones para el tratamiento contra una enfermedad o trastorno. | |
| MX2022007626A (es) | Combinaciones. | |
| MX2022007623A (es) | Combinaciones. | |
| CR20230323A (es) | Quinolinas y azaquinolinas como inhibidores de cd38 | |
| MX2019011506A (es) | Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer. | |
| MX2021010152A (es) | Moduladores de la expresion de malat1. | |
| CL2021001246A1 (es) | Moduladores de expresión irf5. | |
| PE20210109A1 (es) | Moduladores de la expresion de irf4 | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| MX2021002761A (es) | Metodos para tratar la pancreatitis. | |
| CO2024015614A2 (es) | Inhibidores de pi3kα | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| MX2021006915A (es) | Inhibidores de cxcr7 para el tratamiento de cancer. |